RT Journal Article
T1 Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis
A1 Triguero-Martínez, Ana
A1 Fuente, Hortensia de la
A1 Montes, Nuria
A1 Ortiz, Ana María
A1 Roy-Vallejo, Emilia
A1 Castañeda, Santos
A1 González-Alvaro, Isidoro
A1 Lamana Domínguez, Amalia
AB Galectin 1 (Gal1) is a lectin with a wide cellular expression that functions as a negative regulator of the immune system in several animal models of autoimmune diseases. Identification of patients with rheumatoid arthritis (RA) has improved during the last decade, although there is still a need for biomarkers allowing an early diagnosis. In this regard, it has been recently proposed that Gal1 serum levels are increased in patients with RA compared to the general population. However, this topic is controversial in the literature. In this work, we provide additional information about the potential usefulness of Gal1 serum levels as a biomarker for RA diagnosis. We studied Gal1 serum and synovial fluid levels and clinical parameters in samples from 62 patients with early arthritis belonging to the PEARL study. In addition, 24 healthy donors were studied. We found that both patients fulfilling RA criteria and patients with undifferentiated arthritis showed higher Gal1 levels than healthy donors. Similar findings were observed in synovial fluid, which showed even higher levels than serum. However, we did not find correlation between Gal1 levels and disease activity or disability. Therefore, our results suggest that Gal1 could be a diagnostic but not a severity biomarker.
PB Nature Research
YR 2020
FD 2020
LK https://hdl.handle.net/20.500.14352/93966
UL https://hdl.handle.net/20.500.14352/93966
LA eng
NO Triguero-Martínez, A., de la Fuente, H., Montes, N. et al. Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis. Sci Rep 10, 17799 (2020). https://doi.org/10.1038/s41598-020-74185-8
NO FundingEste trabajo fue apoyado por las subvenciones RD16/0011/0012 y PI18/0371 a IG-A, y PI12/01578 a SC del Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) y cofinanciado por el Fondo Europeo de Desarrollo Regional. (FEDER). Actualmente, AT-M cuenta con una beca de doctorado de la Comunidad de Madrid (PEJD-2019-PRE/BMD-16851). Actualmente el NM se encuentra otorgado mediante RD16/0011/0012. El trabajo de ER-V cuenta actualmente con una subvención Rio-Hortega CM19/00149 del Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER).
NO Instituto de Salud Carlos III 
NO Comunidad de Madrid
NO Ministerio de Economía y Competitividad (España)
NO European Commission
DS Docta Complutense
RD 14 dic 2025